91 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
. Prescription drug promotional materials must be submitted to the FDA at the time of their first use. Changes to certain conditions established in an approved … things: issue warning letters; request modifications to promotional materials or require us to provide corrective information to healthcare
DEFA14A
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Additional proxy soliciting materials
4:55pm
by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12
X4 Pharmaceuticals, Inc
D
ssaukd
1 Jun 23
$65.02 mm in equity / options / securities to be acquired, sold $65.02 mm, 22 investors
4:40pm
8-K
u6f21
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
DEFA14A
5bnfn3e jencrws
27 Apr 23
Additional proxy soliciting materials
4:23pm
DEFA14A
36cow
25 Apr 23
Additional proxy soliciting materials
4:24pm
8-K
EX-1.1
10optzw5711t nvagbr
9 Dec 22
X4 Pharmaceuticals Announces Proposed Public Offering
8:46am
8-K
npans2g i7r10q7
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm